Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid.

× No keyword cloud information.

18 in total

Review 1. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors: Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal: Clin Rev Allergy Immunol Date: 2018-02 Impact factor: 8.667

Review 2. The continuing evolution of targeted therapy for inflammatory skin disease.

Authors: C Schlapbach; A A Navarini
Journal: Semin Immunopathol Date: 2015-09-30 Impact factor: 9.623

3. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Authors: Meital Oren-Shabtai; Noa Kremer; Moshe Lapidoth; Eran Sharon; Lihi Atzmony; Adi Nosrati; Emmilia Hodak; Daniel Mimouni; Assi Levi
Journal: Drugs Aging Date: 2020-11-24 Impact factor: 3.923

4. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Authors: F Proft; H Schulze-Koops; M Grunke; E Schrezenmeier; F Halleck; J Henes; L Unger; E Schmidt; C Fiehn; A Jacobi; C Iking-Konert; C Kneitz; R E Schmidt; B Bannert; R E Voll; R Fischer-Betz; I Kötter; H P Tony; J Holle; M Aringer; A Erler; F Behrens; G R Burmester; T Dörner
Journal: Z Rheumatol Date: 2018-02 Impact factor: 1.372

5. Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Authors: Yun-Ju Tsai; Yung-Tsu Cho; Chia-Yu Chu
Journal: Am J Clin Dermatol Date: 2022-05-17 Impact factor: 6.233

10. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.

Authors: Aslı Bilgiç Temel; Cumhur Ibrahim Bassorgun; Ayşe Akman-Karakaş; Erkan Alpsoy; Soner Uzun
Journal: Case Rep Dermatol Date: 2017-02-10

First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid.

Review 1. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Review 2. The continuing evolution of targeted therapy for inflammatory skin disease.

3. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

4. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

5. Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Review 6. Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Review 7. Advances in understanding and managing bullous pemphigoid.

Review 8. Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

9. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.

10. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.